Evidence map›Paper›PMID 32561535›Full record

GuidelineStroke and vascular neurology2020

Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of clinical management of ischaemic cerebrovascular diseases.

Liping Liu, Weiqi Chen, Hongyu Zhou, Wanying Duan, Shujuan Li, Xiaochuan Huo, Weihai Xu, Li'an Huang, Huaguang Zheng, Jingyi Liu and 5 more

2 registry-linked trialsOpen access · goldAbstract readPractice GuidelineReview
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Stroke and vascular neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 211 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
211citing papers in PubMed, 14 pooled it
21.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04797013 phase3completednot on this mapstarted 2021, after this paper: background citation

A Phase 3, Multicentre,Open-label, Randomised Controlled, Non-inferiority Trial

TypeinterventionalSponsorBeijing Tiantan HospitalRan2021 to 2022Enrolled1,430ConditionsAcute Ischemic StrokeArmsrt-PA, rhTNK-tPA
NCT07466251 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke (PISTIAS-3): a Randomized, Double-blind, Placebo-controlled Trial

TypeinterventionalSponsorPeking Union Medical College HospitalRan2026 to 2029Enrolled1,212ConditionsAcute Ischemic Stroke AIS, Intracranial Atherosclerosis ICAS, Atherosclerotic PlaqueArmsRecaticimab plus standard therapy, Recaticimab's placebo in combination with standard therapy
3 · Its place in the literature

Who cites it

211 citing papers in PubMed, 14 syntheses or guidelines pooled it, 332 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Guideline
  8. Pooled it
  9. A systematic review and synthesis of global stroke guidelines on behalf of the World Stroke Organization.International journal of stroke : official journal of the International Stroke Society · 2023
    Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

151 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Liping Liu *Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0003-2943-055X
Weiqi Chen *Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-2551-9314
Hongyu Zhou *Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-9130-889X
Wanying DuanDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0003-3527-9454
Shujuan LiDepartment of Neurology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Xiaochuan HuoDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0003-1264-5132
Weihai XuDepartment of Neurology, Peking Union Medical College Hospital, Beijing, China.
Li'an HuangDepartment of Neurology, Guangzhou Overseas Chinese Hospital, The First Affiliated Hospital of JINAN University, Guangzhou, China.
Huaguang ZhengDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0001-6400-5474
Jingyi LiuDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0001-7360-0267
Hui LiuDepartment of Neurology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Yufei WeiDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-1822-7372
Jie XuDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-8320-218X
Yongjun WangDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China yongjunwang@ncrcnd.org.cn.ORCID 0000-0002-9976-2341
Chinese Stroke Association Stroke Council Guideline Writing Committee
Capital Medical University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNFirst Affiliated Hospital of Jinan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimStroke is the leading cause of disability and death in China. Ischaemic stroke accounts for about 60%-80% of all strokes. It is of considerable significance to carry out multidimensional management of ischaemic cerebrovascular diseases. This evidence-based guideline aims to provide the latest detailed and comprehensive recommendations on the diagnosis, treatment and secondary prevention of ischaemic cerebrovascular diseases.

methodsWe had performed comprehensive searches of MEDLINE (via PubMed) (before 30 June 2019), and integrated the relevant information into charts and distributed to the writing group. Writing group members discussed and determined the recommendations through teleconference. We used the level of evidence grading algorithm of Chinese Stroke Association to grade each recommendation. The draft was reviewed by the Guideline Writing Committee of Chinese Stroke Association Stroke and finalised. This guideline is fully updated every 3 years.

resultsThis evidence-based guideline is based on the treatment, care and prevention of ischaemic cerebrovascular diseases, which emphasises on pathogenesis evaluation, intravenous thrombolysis, endovascular therapy, antiplatelet therapy, prevention and treatment of complications, and risk factor management.

conclusionsThis updated guideline presents a framework for the management of ischaemic cerebrovascular diseases. Timely first-aid measures, professional care in the acute stage, and proactive secondary prevention will be helpful to patients.

Indexed as

Brain IschemiaChinaClinical Decision-MakingConsensusDecision Support TechniquesEvidence-Based MedicineHumansNeurologyPredictive Value of TestsRisk FactorsStrokeTime-to-TreatmentTreatment OutcomeDiagnosisGuidelinesIschemic Cerebrovascular DiseasesManagement

Identifiers

PMID32561535
PMCPMC7337371
OpenAlexW3036502738

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.